Famous

Abstract A 62-year-old woman with multiple sclerosis experienced painless loss of vision in both eyes after starting fingolimod. Fundus examination revealed bilateral macular edema confirmed by optical coherence tomography. Fingolimod was discontinued, and a topical nonsteroidal inflammatory drug an...

Full description

Saved in:
Bibliographic Details
Published in:Survey of ophthalmology 2016-07, Vol.61 (4), p.512-519
Main Authors: Kim, Michelle J., MD, Bhatti, M. Tariq, MD, Costello, Fiona, MD, FRCP
Format: Article
Language:English
Subjects:
disease-modifying agents
Female
fingolimod
Fingolimod Hydrochloride - adverse effects
Fingolimod Hydrochloride - therapeutic use
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Macula Lutea - drug effects
Macula Lutea - pathology
macular edema
Macular Edema - chemically induced
Macular Edema - diagnosis
Middle Aged
multiple sclerosis
Multiple Sclerosis - drug therapy
Ophthalmology
optic neuritis
sphingosine-1-phosphate
Tomography, Optical Coherence - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract A 62-year-old woman with multiple sclerosis experienced painless loss of vision in both eyes after starting fingolimod. Fundus examination revealed bilateral macular edema confirmed by optical coherence tomography. Fingolimod was discontinued, and a topical nonsteroidal inflammatory drug and corticosteroid were initiated. Within 2 months, vision returned to baseline with complete resolution of the macular edema.
ISSN:0039-6257
1879-3304
DOI:10.1016/j.survophthal.2015.12.008